ONS/ONCC CHEMOTHERAPY IMMUNOTHERAPY
CERTIFICATE EXAM: COMPREHENSIVE PRACTICE
EXAMINATION STUDY GUIDE | LATEST UPDATE
2026/2027 | ACTUAL EXAM PRACTICE QUESTIONS
AND ANSWERS | EXAM REVIEW | 100% CORRECT
ANSWERS | VERIFIED SOLUTIONS
This comprehensive practice examination is designed for oncology
nurses and healthcare professionals preparing for the ONS/ONCC
Chemotherapy Immunotherapy Certificate Exam. The examination
blueprint reflects the core competencies required for safe and effective
administration of antineoplastic agents, including chemotherapy,
targeted therapy, and immunotherapy. Content areas covered include
foundational science (cell cycle, cancer biology, immunology),
pharmacology and drug classifications, administration and safety
(including hazardous drug handling, vascular access, and extravasation
management), side effect and adverse event management (including
immune-related adverse events and oncologic emergencies), patient
education and psychosocial support, and professional standards and
documentation. All questions are written at the advanced practice level
expected for certification, with detailed rationales provided for each
answer to reinforce learning and support exam readiness. This resource
is intended to help candidates assess their knowledge, identify areas for
further study, and build confidence for the actual certification
examination.
Table of Contents
1. Foundations of Oncology: Cell Cycle, Cancer Biology, and
Immunology
, 2. Chemotherapy Agents: Classifications, Mechanisms, and
Pharmacology
3. Immunotherapy: Mechanisms, Checkpoint Inhibitors, and Biologic
Response Modifiers
4. Safe Handling and Administration of Hazardous Drugs
5. Vascular Access Devices and Infusion Management
6. Extravasation: Prevention, Identification, and Management
7. Adverse Effects and Symptom Management
8. Immune-Related Adverse Events (irAEs)
9. Oncologic Emergencies
10. Patient Education, Psychosocial Support, and Professional
Practice
Question 1: The primary goal of chemotherapy is to:
A) Enhance immune response
B) Destroy rapidly dividing cancer cells
C) Replace surgical treatment
D) Prevent metastasis only
Correct Answer: B
Rationale: Chemotherapy targets rapidly dividing cells, a key
characteristic of cancer cells. While immunotherapy (A) enhances
immune response, and chemotherapy can be used adjuvantly or
neoadjuvantly with surgery (C) and may help prevent metastasis (D), the
primary goal remains the destruction of rapidly dividing malignant cells.
,Question 2: Which cell cycle phase is most vulnerable to the effects of
cell cycle-specific chemotherapy agents?
A) G0 (resting phase)
B) G1 (first growth phase)
C) S (synthesis phase)
D) M (mitotic phase)
Correct Answer: D
Rationale: Many cell cycle-specific chemotherapy agents are most
effective during the M phase (mitosis) when cells are actively dividing.
G0 (A) is the resting phase where cells are not dividing and are generally
resistant to cell cycle-specific agents. G1 (B) and S (C) phases are
targeted by some specific agents, but the M phase is a primary target
for drugs like vinca alkaloids and taxanes.
Question 3: Which of the following is an example of a cell cycle-specific
chemotherapy agent?
A) Cyclophosphamide
B) Cisplatin
C) Vincristine
D) Doxorubicin
Correct Answer: C
Rationale: Vincristine is a vinca alkaloid that acts specifically during the
M phase of the cell cycle by binding to tubulin and preventing
microtubule formation. Cyclophosphamide (A) and Cisplatin (B) are cell
cycle-nonspecific alkylating agents. Doxorubicin (D) is an antitumor
antibiotic that is primarily cell cycle-nonspecific.
Question 4: Immunotherapy primarily works by:
A) Directly killing cancer cells through cytotoxic mechanisms
, B) Suppressing bone marrow activity
C) Enhancing or restoring the body's immune response against cancer
D) Inhibiting DNA synthesis in rapidly dividing cells
Correct Answer: C
Rationale: Immunotherapy enhances or restores the immune system's
ability to recognize and attack cancer cells. Direct killing (A) is more
characteristic of chemotherapy. Bone marrow suppression (B) is an
adverse effect, not a mechanism of action. DNA synthesis inhibition (D)
is a mechanism of some chemotherapy agents, not immunotherapy.
Question 5: Checkpoint inhibitors function by:
A) Blocking cell division directly
B) Preventing angiogenesis
C) Releasing immune system "brakes" to activate T cells
D) Directly destroying T cells
Correct Answer: C
Rationale: Checkpoint inhibitors block inhibitory signals on T cells (such
as PD-1, PD-L1, and CTLA-4), effectively releasing the "brakes" on the
immune system and allowing T cells to attack cancer cells. They do not
directly block cell division (A) or prevent angiogenesis (B). They activate,
rather than destroy, T cells (D).
Question 6: A common immune-related adverse event (irAE) associated
with checkpoint inhibitors is:
A) Alopecia
B) Peripheral neuropathy
C) Colitis
D) Myelosuppression
CERTIFICATE EXAM: COMPREHENSIVE PRACTICE
EXAMINATION STUDY GUIDE | LATEST UPDATE
2026/2027 | ACTUAL EXAM PRACTICE QUESTIONS
AND ANSWERS | EXAM REVIEW | 100% CORRECT
ANSWERS | VERIFIED SOLUTIONS
This comprehensive practice examination is designed for oncology
nurses and healthcare professionals preparing for the ONS/ONCC
Chemotherapy Immunotherapy Certificate Exam. The examination
blueprint reflects the core competencies required for safe and effective
administration of antineoplastic agents, including chemotherapy,
targeted therapy, and immunotherapy. Content areas covered include
foundational science (cell cycle, cancer biology, immunology),
pharmacology and drug classifications, administration and safety
(including hazardous drug handling, vascular access, and extravasation
management), side effect and adverse event management (including
immune-related adverse events and oncologic emergencies), patient
education and psychosocial support, and professional standards and
documentation. All questions are written at the advanced practice level
expected for certification, with detailed rationales provided for each
answer to reinforce learning and support exam readiness. This resource
is intended to help candidates assess their knowledge, identify areas for
further study, and build confidence for the actual certification
examination.
Table of Contents
1. Foundations of Oncology: Cell Cycle, Cancer Biology, and
Immunology
, 2. Chemotherapy Agents: Classifications, Mechanisms, and
Pharmacology
3. Immunotherapy: Mechanisms, Checkpoint Inhibitors, and Biologic
Response Modifiers
4. Safe Handling and Administration of Hazardous Drugs
5. Vascular Access Devices and Infusion Management
6. Extravasation: Prevention, Identification, and Management
7. Adverse Effects and Symptom Management
8. Immune-Related Adverse Events (irAEs)
9. Oncologic Emergencies
10. Patient Education, Psychosocial Support, and Professional
Practice
Question 1: The primary goal of chemotherapy is to:
A) Enhance immune response
B) Destroy rapidly dividing cancer cells
C) Replace surgical treatment
D) Prevent metastasis only
Correct Answer: B
Rationale: Chemotherapy targets rapidly dividing cells, a key
characteristic of cancer cells. While immunotherapy (A) enhances
immune response, and chemotherapy can be used adjuvantly or
neoadjuvantly with surgery (C) and may help prevent metastasis (D), the
primary goal remains the destruction of rapidly dividing malignant cells.
,Question 2: Which cell cycle phase is most vulnerable to the effects of
cell cycle-specific chemotherapy agents?
A) G0 (resting phase)
B) G1 (first growth phase)
C) S (synthesis phase)
D) M (mitotic phase)
Correct Answer: D
Rationale: Many cell cycle-specific chemotherapy agents are most
effective during the M phase (mitosis) when cells are actively dividing.
G0 (A) is the resting phase where cells are not dividing and are generally
resistant to cell cycle-specific agents. G1 (B) and S (C) phases are
targeted by some specific agents, but the M phase is a primary target
for drugs like vinca alkaloids and taxanes.
Question 3: Which of the following is an example of a cell cycle-specific
chemotherapy agent?
A) Cyclophosphamide
B) Cisplatin
C) Vincristine
D) Doxorubicin
Correct Answer: C
Rationale: Vincristine is a vinca alkaloid that acts specifically during the
M phase of the cell cycle by binding to tubulin and preventing
microtubule formation. Cyclophosphamide (A) and Cisplatin (B) are cell
cycle-nonspecific alkylating agents. Doxorubicin (D) is an antitumor
antibiotic that is primarily cell cycle-nonspecific.
Question 4: Immunotherapy primarily works by:
A) Directly killing cancer cells through cytotoxic mechanisms
, B) Suppressing bone marrow activity
C) Enhancing or restoring the body's immune response against cancer
D) Inhibiting DNA synthesis in rapidly dividing cells
Correct Answer: C
Rationale: Immunotherapy enhances or restores the immune system's
ability to recognize and attack cancer cells. Direct killing (A) is more
characteristic of chemotherapy. Bone marrow suppression (B) is an
adverse effect, not a mechanism of action. DNA synthesis inhibition (D)
is a mechanism of some chemotherapy agents, not immunotherapy.
Question 5: Checkpoint inhibitors function by:
A) Blocking cell division directly
B) Preventing angiogenesis
C) Releasing immune system "brakes" to activate T cells
D) Directly destroying T cells
Correct Answer: C
Rationale: Checkpoint inhibitors block inhibitory signals on T cells (such
as PD-1, PD-L1, and CTLA-4), effectively releasing the "brakes" on the
immune system and allowing T cells to attack cancer cells. They do not
directly block cell division (A) or prevent angiogenesis (B). They activate,
rather than destroy, T cells (D).
Question 6: A common immune-related adverse event (irAE) associated
with checkpoint inhibitors is:
A) Alopecia
B) Peripheral neuropathy
C) Colitis
D) Myelosuppression
